Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): consultee and commentator comments on the ACD
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from Roche
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Roy Castle Lung Cancer Foundation
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the British Thoracic Society
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Royal College of Nursing
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from NCRI/Royal College of Physicians/RCR/ACP/JCCO
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from NHS Cornwall and Isles of Scilly
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the Commissioning Support Appraisals Service
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from Eli Lilly
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comment on the appraisal consultation from the British Thoracic Oncology Group
This page was last updated: 08 March 2011